Cargando…

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab

Detalles Bibliográficos
Autores principales:	VandeVrede, Lawren, La Joie, Renaud, Horiki, Sheena, Mundada, Nidhi S., Koestler, Mary, Hwang, Ji-Hye, Ljubenkov, Peter A., Rojas, Julio C., Rabinovici, Gil D., Boxer, Adam L., Seeley, William W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564667/ https://www.ncbi.nlm.nih.gov/pubmed/37725166 http://dx.doi.org/10.1007/s00401-023-02631-8

Ejemplares similares

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
por: Samudra, Niyatee, et al.
Publicado: (2023)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
por: Thatcher, Gregory RJ, et al.
Publicado: (2013)

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
por: VandeVrede, Lawren, et al.
Publicado: (2023)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
por: Siklos, Marton I, et al.
Publicado: (2013)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
por: Berry, Kacey, et al.
Publicado: (2022)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

An NO Donor Approach to Neuroprotective and Procognitive Estrogen Therapy Overcomes Loss of NO Synthase Function and Potentially Thrombotic Risk
por: VandeVrede, Lawren, et al.
Publicado: (2013)

Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome
por: Asken, Breton M., et al.
Publicado: (2023)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
por: Silvestro, Serena, et al.
Publicado: (2022)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology
por: Peet, Bradley T., et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI
por: Windon, Charles, et al.
Publicado: (2022)

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2022)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning
por: Scotton, William J, et al.
Publicado: (2023)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
por: Salloway, Stephen, et al.
Publicado: (2021)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia
por: Luo, Jia, et al.
Publicado: (2015)

Increasing empathic concern relates to salience network hyperconnectivity in cognitively healthy older adults with elevated amyloid-β burden
por: Chow, Tiffany E., et al.
Publicado: (2022)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h70mi4ufhdg3gtoo3jvgum9i06